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Clinical PerspectiveWhat Is New?Our study results suggest that increased left ventricle mass index relates to compromised white matter microstructure, particularly among older adults with clinical symptoms of prodromal dementia, and these early cardiac structural changes may lead to silent cardioembolic ischemia affecting the cerebral microvasculature, causing white matter microstructural changes.What Are the Clinical Implications?Understanding the association between subclinical cardiac structural changes and early alterations in white matter may allow for early detection and prevention of white matter damage, particularly among those with cognitive decline, in whom existing pathology may exacerbate these changes.

Introduction {#jah33306-sec-0008}
============

Left ventricular (LV) hypertrophy (LVH), a pathologic increase in LV mass, is associated with cerebrovascular disease,[1](#jah33306-bib-0001){ref-type="ref"} white matter hyperintensities,[2](#jah33306-bib-0002){ref-type="ref"} and cognitive decline[3](#jah33306-bib-0003){ref-type="ref"} in aging individuals, particularly elders with hypertension.[4](#jah33306-bib-0004){ref-type="ref"}, [5](#jah33306-bib-0005){ref-type="ref"} Increased LV mass index (LV mass/body surface area) is an imaging marker that precedes LVH[6](#jah33306-bib-0006){ref-type="ref"} and reflects subclinical pathologic remodeling of the ventricular wall. Among older adults, LV mass index is associated with stroke,[1](#jah33306-bib-0001){ref-type="ref"} white matter hyperintensities,[7](#jah33306-bib-0007){ref-type="ref"} and global cognitive decline.[8](#jah33306-bib-0008){ref-type="ref"}, [9](#jah33306-bib-0009){ref-type="ref"} Despite these associations, it is unknown if subclinical changes in the ventricular wall correlate with more sensitive measures of white matter microstructure, such as diffusion tensor imaging (DTI), or specific cognitive domains among older adults.

The current study sought to examine the association between LV mass index obtained by cardiac magnetic resonance and DTI measures of white matter microstructure and neuropsychological performance among older individuals with normal cognition (NC) and mild cognitive impairment (MCI), a prodromal stage of dementia. Given prior research linking overt LVH to cognitive impairment[3](#jah33306-bib-0003){ref-type="ref"} and white matter lesions,[2](#jah33306-bib-0002){ref-type="ref"} we hypothesized that higher LV mass index would correlate with compromised white matter microstructure on DTI and worse neuropsychological performance (especially memory).[10](#jah33306-bib-0010){ref-type="ref"} Secondarily, we tested whether associations differed by cognitive diagnosis.

Methods {#jah33306-sec-0009}
=======

Study Cohort {#jah33306-sec-0010}
------------

The Vanderbilt Memory & Aging Project[11](#jah33306-bib-0011){ref-type="ref"} is a longitudinal observational study investigating vascular health and brain aging, enriched with older adults with MCI.[12](#jah33306-bib-0012){ref-type="ref"} Inclusion required participants be ≥60 years, speak English, have adequate auditory and visual acuity, and have a reliable study partner. As part of a comprehensive screening, participants were excluded for a cognitive diagnosis other than NC, early MCI,[13](#jah33306-bib-0013){ref-type="ref"} or MCI,[12](#jah33306-bib-0012){ref-type="ref"} magnetic resonance imaging contraindication, history of neurological disease (eg, multiple sclerosis, stroke), heart failure, major psychiatric illness, head injury with loss of consciousness \>5 minutes, or a systemic or terminal illness affecting follow‐up participation. At enrollment, participants completed a comprehensive examination, including (but not limited to) fasting blood draw, physical examination, clinical interview, medication review, neuropsychological assessment, echocardiogram, cardiac magnetic resonance, and multimodal brain magnetic resonance imaging. Participants were excluded from this study for missing predictor, outcome, or covariate data. See Figure [1](#jah33306-fig-0001){ref-type="fig"} for inclusion/exclusion details. The protocol was approved by the Vanderbilt University Medical Center Institutional Review Board. Written informed consent was obtained from participants before data collection. Due to participant consent restrictions in data sharing, a subset of data is available to others for purposes of reproducing the results or replicating procedures. These data, analytic methods, and study materials can be obtained by contacting the corresponding author.

![Participant inclusion/exclusion details. Missing data categories are mutually exclusive. Thirty‐nine total participants with LVH,CVD, or atrial fibrillation were excluded for sensitivity analyses (LVH n=10; CVD n=10; atrial fibrillation n=15; LVH and atrial fibrillation n=3; CVD and atrial fibrillation n=1). CVD indicates cardiovascular disease; DTI, diffusion tensor imaging; LV, left ventricular; LVH, left ventricular hypertrophy; MCI, mild cognitive impairment; NC, normal cognition.](JAH3-7-e009041-g001){#jah33306-fig-0001}

Cardiac Magnetic Resonance {#jah33306-sec-0011}
--------------------------

Cardiac magnetic resonance was acquired at Vanderbilt University Medical Center using a 1.5‐T Siemens Avanto system (Siemens Medical Solutions USA, Inc, Malvern, PA) with a phased‐array torso receiver coil. LV and right ventricular volume and function were assessed using a breath‐hold, ECG‐synchronized, cine steady‐state free precession sequence with the following parameters: TR=180 milliseconds, TE=1.1 milliseconds, flip angle=80°, field of view=300 to 340 mm, and 156×192 matrix. Under the supervision of a board‐certified radiologist (J.J.C.), trained analysts blinded to clinical information (J.G.T., S.N.) used QMass MR 7.6 Enterprise Solution (Medis, Leiden, the Netherlands) to define LV endocardial and epicardial contours at end systole and end diastole on short‐axis images. LV end systole and end diastole volumes were calculated using Simpson\'s rule. Papillary muscles were considered part of the blood pool and excluded from LV mass calculation. LV mass was calculated at end diastole by summing the myocardial area for each slice, multiplying by slice thickness plus slice gap, and multiplying by 1.05 g/mL (the density of the myocardium). LV mass index was defined as LV mass/body surface area.

Neuropsychological Assessment {#jah33306-sec-0012}
-----------------------------

Participants completed a neuropsychological protocol assessing language, information‐processing speed, executive functioning, visuospatial skills, and episodic memory. Measures were carefully selected to preclude floor or ceiling effects and were not used to screen or select participants into the study.

Brain Magnetic Resonance Imaging {#jah33306-sec-0013}
--------------------------------

Participants were scanned at the Vanderbilt University Institute of Imaging Science on a 3‐T Philips Achieva system (Best, the Netherlands) using an 8‐channel SENSE reception coil array as part of a multimodal acquisition protocol. DTI data were acquired along 32 diffusion gradient vectors (repetition time/echo time=10 000/60 milliseconds, spatial resolution=2×2×2 mm^3^, b‐value=1000 s/mm^2^) and postprocessed through an established tract‐based spatial statistics pipeline using the Functional Magnetic Resonance Imaging of the Brain Software Library version 4.1.4 (<http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSL>).[14](#jah33306-bib-0014){ref-type="ref"}

Data were corrected for motion and eddy currents. A brain mask was created, the diffusion tensor model was fit using Functional Magnetic Resonance Imaging of the Brain\'s Diffusion Toolbox, and fractional anisotropy (FA), mean diffusivity, radial diffusivity, and axial diffusivity values were calculated. All FA images were nonlinearly registered and merged into a 4‐dimensional image, and a mean image was created. The mean image was used to generate a mean skeleton to which a threshold was applied to exclude voxels that did not overlap among ≥80% of participants. Each participant\'s FA image was projected onto the mean skeleton, and these skeleton projections were combined into a single 4‐dimensional file containing skeletonized FA data from all participants. Nonlinear registration was also applied to the mean diffusivity, radial diffusivity, and axial diffusivity images for each participant. For each individual metric, all participant data were merged into a single 4‐dimensional file that was projected onto the original mean FA skeleton.

Analytical Plan {#jah33306-sec-0014}
---------------

Systolic blood pressure was the mean of 2 measurements. Diastolic blood pressure was the mean of 2 measurements. Medication review determined antihypertensive medication use. Hypertension was defined as antihypertensive medication usage, systolic blood pressure ≥140 mm Hg, or diastolic blood pressure ≥90 mm Hg. Diabetes mellitus was defined as fasting blood glucose ≥126 mg/dL, hemoglobin A~1c~ ≥6.5%, or oral hypoglycemic or insulin medication usage. Current cigarette smoking (yes/no within previous year) was ascertained by self‐report. LVH was defined on echocardiogram as LV mass index \>115 g/m^2^ in men or \>95 g/m^2^ in women. Self‐report atrial fibrillation was corroborated by any 1 of the following sources: echocardiogram, documentation of prior procedure/ablation for atrial fibrillation, or medication usage for atrial fibrillation. Self‐report prevalent cardiovascular disease (CVD) with supporting evidence from available medical records included coronary heart disease, angina, or myocardial infarction (note, heart failure was a parent study exclusion). Framingham Stroke Risk Profile (FSRP) score applied points by sex for age, systolic blood pressure, antihypertensive medication usage, diabetes mellitus, current cigarette smoking, atrial fibrillation, LVH, and prevalent CVD.[15](#jah33306-bib-0015){ref-type="ref"} For this study, age was included in the statistical models as a separate covariate, and LV mass index was the predictor, so points assigned to age and LVH were removed from the FSRP score. Apolipoprotein E (*APOE*) genotyping was quantified from DNA extracted from whole blood samples.[11](#jah33306-bib-0011){ref-type="ref"} *APOE‐ε4* carrier status was defined as positive (ε2/ε4, ε3/ε4, ε4/ε4) or negative (ε2/ε2, ε2/ε3, ε3/ε3).

Voxelwise analyses using general linear models and the Functional Magnetic Resonance Imaging of the Brain Software Library randomise with 5000 permutations related LV mass index (g/m^2^) to FA, mean diffusivity, radial diffusivity, and axial diffusivity, adjusting for age, sex, education, race/ethnicity, FSRP (excluding points assigned to age and LVH), cognitive diagnosis, and *APOE‐ε4* status. Excluding the small subset of participants with early MCI, models were repeated evaluating an *LV mass index×cognitive diagnosis* interaction term followed by stratification by cognitive diagnosis (NC, MCI). In post hoc analyses the effect of hypertension was examined by relating an *LV mass index×hypertension* interaction to DTI metrics adjusting for age, sex, education, race/ethnicity, FSRP (excluding points assigned to age, LVH, and systolic blood pressure accounting for antihypertensive medication utilization), cognitive diagnosis, and *APOE‐ε4* status. Models were repeated stratifying by hypertension status (yes, no). Multiple comparison correction was performed using the established cluster enhancement permutation procedure in the Functional Magnetic Resonance Imaging of the Brain Software Library.[16](#jah33306-bib-0016){ref-type="ref"} The threshold for statistical significance was set a priori as corrected *P*\<0.05, and sensitivity analyses, removing participants with LVH, prevalent CVD, or atrial fibrillation, were performed. Parametric estimates of statistically significant associations were calculated in R version 3.2.1 (<http://www.r-project.org>) using least‐squares regression for illustration and interpretation.

Linear regression models with ordinary least‐squares estimates related LV mass index to neuropsychological performance (1 variable per model), adjusting for identical covariates. Excluding the small subset of participants with early MCI, models were repeated evaluating an LV mass index×cognitive diagnosis interaction term followed by stratification by cognitive diagnosis (NC, MCI). In post hoc analyses, the effect of hypertension was examined by relating an LV mass index×hypertension interaction to neuropsychological performance (1 variable per model) adjusting for age, sex, education, race/ethnicity, FSRP (excluding points assigned to age, LVH, and systolic blood pressure accounting for antihypertensive medication utilization), cognitive diagnosis, and *APOE‐ε4* status. Models were repeated stratified by hypertension status (yes, no). For significant models, follow‐up sensitivity analyses excluded participants with LVH, prevalent CVD, or atrial fibrillation to test if these conditions accounted for the results. Significance was set a priori at *P*\<0.05, and analyses were conducted using R.

Results {#jah33306-sec-0015}
=======

Participant Characteristics {#jah33306-sec-0016}
---------------------------

For participants in the neuropsychological (n=318, 73±7 years, 58% male, 87% non‐Hispanic white) and the DTI samples (n=313, 73±7 years, 57% male, 87% non‐Hispanic white), LV mass index ranged 29.5 to 91.1 g/m^2^. See Table [1](#jah33306-tbl-0001){ref-type="table"} for participant characteristics of the neuropsychological sample and DTI sample, stratified by NC, early MCI, and MCI.

###### 

Participant Characteristics

                                                                          Neuropsychological Sample   DTI Sample                                                                                                                                                                                                              
  ----------------------------------------------------------------------- --------------------------- ------------ ----------- ----------- ---------------------------------------------------------------------------------------------------------------------------------- ----------- ----------- ----------- ----------- ----------------------------------------------------------------------------------------------------------------------------------
  Demographic and health characteristics                                                                                                                                                                                                                                                                                      
  Age, y                                                                  73±7                        72±7         73±6        73±8        0.69                                                                                                                               73±7        72±7        73±6        73±7        0.73
  Sex, % male                                                             58                          58           74          55          0.20                                                                                                                               58          58          74          56          0.21
  Race, % Non‐Hispanic white                                              87                          88           85          86          0.81                                                                                                                               87          88          85          87          0.92
  Education, y                                                            16±3                        16±2         16±3        15±3        \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}                                            16±3        16±2        16±3        15±3        \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}
  *APOE‐ε4*, % positive                                                   34                          29           22          44          0.01[b](#jah33306-note-0004){ref-type="fn"}                                                                                        35          29          22          45          \<0.006[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}
  FSRP, total score[c](#jah33306-note-0005){ref-type="fn"}                12±4                        12±4         13±3        13±4        0.02[b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}                                               12±4        12±4        13±3        13±4        0.03[b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}
  Systolic blood pressure, mm Hg                                          142±18                      140±17       150±18      145±19      0.003[b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}                                              142±18      140±17      150±18      145±19      0.005[b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}
  Antihypertensive medication usage, %                                    53                          52           56          54          0.88                                                                                                                               53          52          56          53          0.95
  Diabetes mellitus, %                                                    18                          14           22          22          0.18                                                                                                                               17          14          22          20          0.34
  Current smoking, %                                                      2                           1            4           3           0.44                                                                                                                               2           1           4           3           0.44
  Atrial fibrillation, %                                                  6                           5            11          6           0.43                                                                                                                               6           5           11          7           0.44
  Prevalent CVD, %                                                        3                           4            0           3           0.53                                                                                                                               4           4           0           3           0.53
  Left ventricular hypertrophy, %                                         4                           2            4           6           0.23                                                                                                                               4           2           4           7           0.22
  Left ventricular mass index, g/m^2^                                     51.0±9.9                    50.6±10.2    53.3±8.0    51.0±9.9    0.35                                                                                                                               51.0±10.0   50.7±10.3   53.3±8.0    51.0±10.0   0.38
  Neuropsychological performance[e](#jah33306-note-0007){ref-type="fn"}                                                                                                                                                                                                                                                       
  Montreal Cognitive Assessment                                           25.4±3.2                    27.0±2.2     25.4±2.4    23.2±3.3    \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}   25.4±3.2    27.0±2.2    25.4±2.4    23.3±3.3    \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}
  Boston Naming Test                                                      26.8±3.1                    27.9±2.0     26.6±2.4    25.3±3.8    \<0.001[b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}                                            26.8±3.1    27.9±2.0    26.6±2.4    25.4±3.7    \<0.001[b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}
  Animal Naming                                                           18.9±5.4                    20.9±4.8     19.4±3.4    16.2±5.2    \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}                                            19.0±5.4    21.0±4.8    19.4±3.4    16.2±5.3    \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}
  WAIS‐IV Digit‐Symbol Coding                                             52.7±12.8                   57.5±11.5    53.4±11.2   46.3±12.1   \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}                                            52.9±12.7   57.4±11.6   53.4±11.2   46.7±11.9   \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}
  DKEFS Number Sequencing, s                                              42.0±18.9                   35.9±12.6    42.0±13.2   50.3±23.4   \<0.001[b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}                                            42.1±19.1   35.9±12.7   42.0±13.2   50.5±23.6   \<0.001[b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}
  Executive Function Composite                                            0.0±0.9                     0.4±0.6      0.2±0.4     −0.6±1.0    \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}   0.0±0.9     0.4±0.6     0.2±0.4     −0.6±1.0    \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}
  DKEFS Letter Number Switching, s                                        107±48                      87±34        93±22       138±52      \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}   107±48      87±34       93±22       138±53      \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}
  DKEFS Tower Test                                                        15.0±4.7                    16.1±4.3     16.2±3.5    13.2±4.7    \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}                                            15.0±4.7    16.2±4.3    16.2±3.5    13.2±4.8    \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}
  DKEFS Color‐Word Inhibition, s                                          69.2±23.5                   60.0±13.5    74.6±15.5   80.0±29.6   \<0.001[b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}                                            69.1±23.6   60.0±13.6   74.6±15.5   79.8±29.9   \<0.001[b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}
  Letter Fluency (FAS) Test                                               38.7±11.6                   42.9±11.4    37.9±11.1   33.3±9.7    \<0.001[b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}                                            38.8±11.6   42.8±11.5   37.8±11.1   33.5±9.7    \<0.001[b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}
  Hooper Visual Organization Test                                         24.5±3.1                    25.4±2.5     24.7±2.2    23.3±3.6    \<0.001[b](#jah33306-note-0004){ref-type="fn"}                                                                                     24.5±3.1    25.4±2.5    24.7±2.2    23.3±3.7    \<0.001[b](#jah33306-note-0004){ref-type="fn"}
  Memory Composite                                                        0.0±1.0                     0.6±0.7      −0.1±0.8    −0.7±0.8    \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}   0.0±1.0     0.6±0.7     −0.1±0.8    −0.7±0.7    \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}
  CVLT‐II Trials 1 to 5 Total Learning                                    40.6±11.8                   47.1±9.3     40.1±9.7    32.1±9.6    \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}   40.6±11.8   47.0±9.3    40.1±9.7    32.1±9.7    \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}
  CVLT‐II Long Delay Free Recall                                          8.1±4.2                     10.5±3.3     7.6±3.5     5.1±3.4     \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}   8.1±4.2     10.5±3.3    7.6±3.5     5.0±3.5     \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}
  CVLT‐II Recognition                                                     2.4±1.0                     3.0±0.7      2.3±0.8     1.7±0.9     \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}   2.4±1.0     3.0±0.7     2.3±0.8     1.8±0.9     \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}
  BFLT Trials 1 to 5 Total Learning                                       113±41                      136±30       110±28      82±35       \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}   113±41      136±30      110±28      82±35       \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}
  BFLT Long Delay Recall                                                  27.0±10.4                   32.6±7.5     28.0±6.6    19.4±9.7    \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}   27.0±10.4   32.5±7.5    28.0±6.6    19.5±9.8    \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}
  BFLT Recognition                                                        0.7±0.2                     0.8±0.2      0.7±0.2     0.6±0.2     \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}   0.7±0.2     0.8±0.2     0.7±0.2     0.6±0.2     \<0.001[a](#jah33306-note-0003){ref-type="fn"}, [b](#jah33306-note-0004){ref-type="fn"}, [d](#jah33306-note-0006){ref-type="fn"}

Values are displayed as mean±SD or frequency. Participant characteristics were compared across cognitive diagnosis using Kruskal‐Wallis test for continuous variables and chi‐squared test for categorical variables. *APOE* indicates apolipoprotein E; BFLT, Biber Figure Learning Test; Boston Naming Test, Boston Naming Test‐30 Item Odd Version; CVD, cardiovascular disease; CVLT‐II, California Verbal Learning Test, 2nd Edition; DKEFS, Delis‐Kaplan Executive Function System; DTI, diffusion tensor imaging; FSRP, Framingham Stroke Risk Profile; MCI, mild cognitive impairment; NC, normal cognition; WAIS‐IV, Wechsler Adult Intelligence Scale, 4th Edition.

Early MCI different than MCI.

NC different from MCI.

A modified FSRP score was included in statistical models excluding points assigned to age and LVH (Total=6±3, NC=6±3, Early MCI=7±3, MCI=7±3).

NC different from Early MCI.

All neuropsychological performance values are shown as total correct excluding timed tasks, which are represented by s=seconds.

LV Mass Index and DTI Metrics {#jah33306-sec-0017}
-----------------------------

LV mass index was negatively correlated with FA primarily in the superior frontal gyrus (corrected *P*\<0.049). LV mass index was positively associated with mean diffusivity primarily in the anterior corona radiata (corrected *P*=0.003). LV mass index was also positively associated with radial diffusivity, primarily in the medial orbital gyrus (corrected *P*=0.004). Finally, LV mass index was positively associated with axial diffusivity in the superior corona radiata (corrected *P*=0.002; see Figure [2](#jah33306-fig-0002){ref-type="fig"} and Table [2](#jah33306-tbl-0002){ref-type="table"} for details). Associations with mean, radial, and axial diffusivity persisted after exclusion for LVH, CVD, and atrial fibrillation (corrected *P*\<0.05; Table [S1](#jah33306-sup-0001){ref-type="supplementary-material"}).

![LV mass index and mean diffusivity. Association between LV mass index and mean diffusivity. Skeletons show regions where LV mass index is positively associated with mean diffusivity in the whole sample (n=313), NC participants only (n=164), and MCI participants only (n=122). No significance was seen in the NC group. Images taken at Z=91. L indicates left; LV, left ventricular; MCI, mild cognitive impairment; NC, normal cognition; R, right.](JAH3-7-e009041-g002){#jah33306-fig-0002}

###### 

Region‐Specific LV Mass Index Associations With DTI Metrics

                                 Anatomical Region         Hemisphere   Volume (mm^3^)   Cluster Statistics   Corrected *P* Value[c](#jah33306-note-0011){ref-type="fn"}   MNI Coordinate[d](#jah33306-note-0012){ref-type="fn"}               
  ------------------------------ ------------------------- ------------ ---------------- -------------------- ------------------------------------------------------------ ------------------------------------------------------- ----- ----- -----
  Fractional anisotropy          Superior frontal gyrus    Right        12 111           −0.296               9.60×10^−7^                                                  0.016                                                   17    −12   52
  Precentral gyrus               Left                      269          −0.309           1.75×10^−6^          0.047                                                        −18                                                     −16   49    
  Precuneus                      Left                      216          −0.267           2.15×10^−5^          0.047                                                        −20                                                     −51   44    
  Posterior thalamic radiation   Left                      89           −0.198           1.54×10^−3^          0.048                                                        −29                                                     −71   10    
  Inferior frontal gyrus         Right                     63           −0.198           1.39×10^−3^          0.048                                                        28                                                      33    6     
  Posterior thalamic radiation   Left                      22           −0.205           1.18×10^−3^          0.049                                                        −33                                                     −64   0     
  Mean diffusivity               Anterior corona radiata   Right        50 234           0.264                7.69×10^−6^                                                  0.003                                                   17    33    −12
  Radial diffusivity             Medial orbital gyrus      Left         49 411           0.259                1.04×10^−5^                                                  0.004                                                   −19   16    −18
  Axial diffusivity              Superior corona radiata   Right        33 798           0.325                1.20×10^−8^                                                  0.002                                                   19    7     34

DTI indicates diffusion tensor imaging; LV, left ventricular; MNI, Montreal Neurological Institute.

β is standardized.

Parametric *P*‐values were calculated using least‐squares regression to relate raw DTI values extracted from each participant skeleton and LV mass index.

*P*‐value has been corrected for multiple comparisons.

Coordinates represent the voxel with the minimum *P*‐value in each cluster.

LV mass index did not interact with cognitive diagnosis on any DTI metric (corrected *P*\>0.3). However, diagnostic stratification revealed that LV mass index was associated with DTI metrics among MCI participants. Specifically, LV mass index positively related to mean diffusivity (corrected *P*=0.015) and axial diffusivity (corrected *P*\<0.05) primarily in the superior corona radiata, and radial diffusivity (corrected *P*=0.016) in the striatum (Figure [2](#jah33306-fig-0002){ref-type="fig"}, Table [S2](#jah33306-sup-0001){ref-type="supplementary-material"}). The association with mean diffusivity persisted after exclusion for LVH, CVD, and atrial fibrillation (corrected *P*\<0.049; Table [S1](#jah33306-sup-0001){ref-type="supplementary-material"}), whereas the associations with radial diffusivity (corrected *P*=0.073) and axial diffusivity (corrected *P*=0.068) were modestly attenuated. LV mass index was unrelated to FA (corrected *P*\>0.066) among MCI participants. LV mass index was unrelated to any DTI metric among NC participants (corrected *P*\>0.15; Figure [2](#jah33306-fig-0002){ref-type="fig"}).

LV mass index did not interact with hypertension on any DTI metric (corrected *P*\>0.13). However, stratification by hypertension status revealed that LV mass index was associated with DTI metrics among hypertensive participants. LV mass index was negatively associated with FA primarily in the superior frontal gyrus (corrected *P*\<0.05). LV mass index was positively associated with mean diffusivity (corrected *P*=0.002) in the superior corona radiata, radial diffusivity (corrected *P*=0.004) in the inferior temporal gyrus, and axial diffusivity (corrected *P*\<0.001) in the straight gyrus (see Table [S3](#jah33306-sup-0001){ref-type="supplementary-material"} for details). The associations with mean, radial, and axial diffusivity persisted after exclusion for LVH, CVD, and atrial fibrillation (corrected *P*\<0.041; Table [S1](#jah33306-sup-0001){ref-type="supplementary-material"}). LV mass index was unrelated to any DTI metric among normotensive participants (corrected *P*\>0.17).

LV Mass Index and Neuropsychological Performances {#jah33306-sec-0018}
-------------------------------------------------

Among all participants, LV mass index only related to Biber Figure Learning Test Recognition performance (β=−0.003, *P*=0.036), an association that remained significant after exclusion for LVH, CVD, and atrial fibrillation (β=−0.003, *P*=0.045). LV mass index did not interact with cognitive diagnosis on neuropsychological performance, and diagnostic stratification results were null (see Table [3](#jah33306-tbl-0003){ref-type="table"} for details). LV mass index did not interact with hypertension on neuropsychological performance (*P*\>0.13). However, stratification revealed LV mass index associations with Biber Figure Learning Test Recognition performance (β=−0.005, *P*=0.03) and Biber Figure Learning Test Total Trials (β=−0.949, *P*=0.045) among normotensive participants. The association with Biber Figure Learning Test Recognition remained significant after exclusion for LVH, CVD, and atrial fibrillation (β=−0.007, *P*=0.03). LV mass index was unrelated to neuropsychological performance among hypertensive participants (*P*\>0.18; see Table [S4](#jah33306-sup-0001){ref-type="supplementary-material"} for details).

###### 

LV Mass Index Associations With Neuropsychological Performance

                                         β        95% Confidence Interval   *P* Value
  -------------------------------------- -------- ------------------------- -----------
  Boston Naming Test                     0.007    −0.030, 0.043             0.72
  Animal Naming                          −0.026   −0.088, 0.035             0.39
  WAIS‐IV Coding                         −0.031   −0.178, 0.115             0.67
  DKEFS Number Sequencing, s             −0.079   −0.303, 0.145             0.49
  Executive Function Composite           0.003    −0.006, 0.012             0.52
  DKEFS Letter Number Switching, s       −0.166   −0.674, 0.341             0.52
  DKEFS Tower Test                       0.035    −0.022, 0.093             0.23
  DKEFS Color‐Word Inhibition, s         −0.008   −0.290, 0.274             0.95
  Letter Fluency (FAS) Test              −0.032   −0.170, 0.106             0.65
  Hooper Visual Organization Test        −0.011   −0.049, 0.027             0.56
  Memory Composite                       −0.001   −0.010, 0.009             0.91
  CVLT‐II Trials 1 to 5 Total Learning   0.008    −0.111, 0.127             0.90
  CVLT‐II Long Delay Free Recall         0.007    −0.036, 0.050             0.75
  CVLT‐II Recognition                    0.002    −0.008, 0.013             0.66
  BFLT Trials 1 to 5 Total Learning      −0.262   −0.665, 0.141             0.20
  BFLT Long Delay Recall                 −0.092   −0.200, 0.016             0.09
  BFLT Recognition                       −0.003   −0.005, −0.0002           0.04

Analyses performed on n=318 participants. Participants missing a subset of neuropsychological test performances were excluded in a pairwise fashion to maximize data available for analyses. Models were adjusted for age, sex, education, race/ethnicity, Framingham stroke risk profile (excluding points assigned for age and LVH), cognitive diagnosis, and *APOE‐*ε*4* status. *APOE* indicates apolipoprotein E; BFLT, Biber Figure Learning Test; Boston Naming Test, Boston Naming Test‐30 Item Odd Version; CVLT‐II, California Verbal Learning Test, 2nd Edition; DKEFS, Delis‐Kaplan Executive Function System; LV, left ventricular; LVH, LV hypertrophy; WAIS‐IV, Wechsler Adult Intelligence Scale, 4th Edition.

Discussion {#jah33306-sec-0019}
==========

Among our community‐dwelling cohort of older adults without a clinical history of stroke, dementia, or heart failure, higher LV mass index was associated with compromised white matter microstructure measured with DTI. Specifically, LV mass index was negatively associated with FA and positively associated with mean, radial, and axial diffusivity. Follow‐up stratified analyses revealed that these findings were present in MCI and hypertensive participants only. Together, these results suggest that higher LV mass index, a subclinical marker of cardiovascular structure, is associated with declining white matter microstructure in cognitively symptomatic individuals, independent of LVH, CVD, or atrial fibrillation.

This study is among the first to report an association between LV mass index and white matter microstructure as measured by DTI. Several pathways may account for this connection. First, increased LV mass index and compromised white matter microstructure may be explained by a common etiology, such as hypertension. As the left ventricle pumps against a high‐pressure arterial system over time, the myocardium hypertrophies[17](#jah33306-bib-0017){ref-type="ref"} to provide enough force for adequate perfusion. Thus, hypertension directly contributes to LV remodeling and has been shown to directly lead to changes in the cerebral vasculature, damaging the white matter.[18](#jah33306-bib-0018){ref-type="ref"} Alternatively, the increase in LV mass index could directly contribute to diminished white matter microstructure by reducing cardiac functional efficiency. For example, when the left ventricle hypertrophies, the electrical tracts in the myocardium lengthen, increasing the risk for cardiac arrhythmias.[17](#jah33306-bib-0017){ref-type="ref"} As the synchronized conduction of the heart becomes compromised, risk for blood stasis increases,[19](#jah33306-bib-0019){ref-type="ref"} potentially leading to thrombus formation.[17](#jah33306-bib-0017){ref-type="ref"} Therefore, those older adults with increased LV mass index could experience silent cardioembolic ischemia, leading to subclinical brain microvascular changes. This hypothesis is consistent with research showing that LV remodeling is associated with asymptomatic changes in cerebral white matter.[20](#jah33306-bib-0020){ref-type="ref"} Such pathologic cerebral vasculature changes may contribute to axonal damage[21](#jah33306-bib-0021){ref-type="ref"} or incite inflammatory processes,[22](#jah33306-bib-0022){ref-type="ref"} both of which have been associated with white matter microstructure changes.[23](#jah33306-bib-0023){ref-type="ref"} Thus, early changes in the ventricle wall, preceding an LVH diagnosis, may correspond with pathologic changes in white matter microstructure captured by DTI.

Among the entire sample, LV mass index was associated with all 4 DTI metrics in both anterior and posterior regions of the brain, suggesting a global effect on white matter microstructure, not specific to 1 degenerative process or region. Although anatomic regions where the associations are most prominent can be identified, the associations are not restricted to these regions and likely represent a global process, as illustrated by the skeleton image in Figure [2](#jah33306-fig-0002){ref-type="fig"}.

The findings presented here also suggest that the association between LV mass index and DTI is modified by cognitive diagnosis and hypertension. Although there was not an interaction with cognitive diagnosis, and stratified results must be interpreted with caution, LV mass index was globally associated with diminished white matter microstructure among MCI participants, whereas results were null among NC participants. One explanation is that a higher degree of white matter microstructural damage, as seen in MCI,[24](#jah33306-bib-0024){ref-type="ref"} may be necessary before LV mass index relates to DTI measurements. MCI participants are more likely to have amyloid and tau pathology,[25](#jah33306-bib-0025){ref-type="ref"} which have been associated with white matter damage.[26](#jah33306-bib-0026){ref-type="ref"} It is possible that in the presence of pathology and more susceptible white matter, as seen in MCI, small changes in LV structure lead to greater changes in white matter microstructure. Additionally, although the interaction between LV mass index and hypertension was not statistically significant, stratified results suggest that LV mass index was associated with diminished white matter microstructure among hypertensive, but not normotensive, participants. This association, which should be interpreted with caution, is consistent with prior work showing the associations among hypertension, LV mass index,[17](#jah33306-bib-0017){ref-type="ref"} and white matter disease.[18](#jah33306-bib-0018){ref-type="ref"} Those with longstanding hypertension may have some underlying structural brain changes present,[27](#jah33306-bib-0027){ref-type="ref"} making the white matter more vulnerable to small changes in LV structure. Future research is needed to understand these group differences.

Our results show a very limited association between LV mass index and cognition, implicating only visuospatial memory. Although this observation is consistent with some prior work,[9](#jah33306-bib-0009){ref-type="ref"}, [10](#jah33306-bib-0010){ref-type="ref"} the remaining null cognitive results contrast with literature reporting cognitive associations with LVH[8](#jah33306-bib-0008){ref-type="ref"} or increased LV mass index[3](#jah33306-bib-0003){ref-type="ref"}, [28](#jah33306-bib-0028){ref-type="ref"} in aging cohorts that include dementia cases. Although increased LV mass index is an early marker of pathologic LV remodeling, it may not strongly correspond with subtle cognitive changes in cognitively normal individuals or elders with only mild prodromal symptoms of dementia, such as those participants studied here. Furthermore, prior work has shown that the association between increased LV mass index and cognition is attenuated when other cardiovascular risk factors are adjusted for,[3](#jah33306-bib-0003){ref-type="ref"}, [8](#jah33306-bib-0008){ref-type="ref"}, [9](#jah33306-bib-0009){ref-type="ref"}, [10](#jah33306-bib-0010){ref-type="ref"} as was done here with the inclusion of a vascular risk score.

The current study has several strengths, including a clinically well characterized cohort emphasizing participants free of clinical dementia along with excellent methods for quantifying white matter microstructure, LV mass index, and neuropsychological performance. Additional strengths include comprehensive ascertainment of potential confounders and the application of a cluster enhancement permutation procedure in the DTI analyses to correct for multiple comparisons, thereby reducing the possibility of a false‐positive finding. Finally, core laboratories using quality control procedures analyzed all magnetic resonance imaging measurements in batch, and technicians were blinded to clinical information. Despite these strengths, the study is cross‐sectional and cannot address causality. Longitudinal studies are needed to understand the temporal nature of associations reported here. Also, the cohort was predominantly non‐Hispanic white with participants 60 to 92 years of age, thus limiting generalizability to other races, ethnicities, and age groups.

The current study demonstrates a novel association between LV mass index and white matter microstructure. Results suggest a connection between early pathologic LV remodeling and compromised white matter microstructure, an observation that is more pronounced in cognitively symptomatic older adults. Additional research is needed to further assess the mechanisms and longitudinal changes related to the associations reported here.
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